ResMed (RMD) Misses Q3 EPS by 2c
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q3 EPS of $2.37, $0.02 worse than the analyst estimate of $2.39. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.29 billion.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
- Kyverna Therapeutics, Inc. (KYTX) Tops Q2 EPS by 45c
- Adecoagro S.A. (AGRO) Misses Q2 EPS by 63c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
